More scientists will get jobs this year, says survey
The UK science labour market has been resilient to the economic downturn, with more skilled scientists being recruited and a significant increase in requirements predicted for contract staff during the next 12 months, a survey has revealed.
SRG's 2009-2010 UK Science Labour Trends Survey questioned organisations in the chemicals, pharmaceuticals, biotechnology and healthcare, oil, petrochemical and food industries.
The survey had 554 respondents, who revealed that biotechnology was second to oil/gas/petrochemicals in employing the most permanent staff in 2009 compared with 2008. Biotechnology is also now near the top in terms of the number of permanent staff it plans to hire across all regions in the UK.
This positive trend continues for contract scientific staff, although the levels of recruitment here are expected to remain stable rather than increase during 2010.
Regionally, the South West and Wales are finding it easiest to recruit permanent scientific staff, while Scotland is struggling. Wales is the one region in which significantly more companies are using fewer staff than a year ago.
The Midlands has seen the biggest downward trend in the use of temporary scientists year on year.
Ena Vieira, biotechnology industry specialist for UK scientific personnel recruitment agency SRG said: "With the unstable economic situation over the last 12 months, biotech companies have become even more focused on the commercial returns of their products. This has led to a trend emerging, showing that they are now seeking to recruit more commercially focused staff while still requiring them to have suitable scientific skills."
She added: "The results of our latest survey clearly show that the outlook for 2010 is looking positive as, from all the sectors surveyed, biotechnology is predicting the second-highest increased permanent staff recruitment during 2010."
You may also like
Manufacturing
Bora Group to acquire MacroGenics’ manufacturing operations and CDMO business
The purchase will hand the Group a biologics drug substance manufacturing facility and a warehousing centre in Maryland, which Bora plans to use in cooperation with Tanvex Biopharma to scale its end-to-end biologics platform
Finance
Cambridge biotech Verinnogen secures £500k CPI investment to advance cancer drug development
The investment will advance a handheld device delivering more precise and reproducible tumour size measurements in preclinical oncology research, addressing variability in existing techniques that can slow drug development and necessitate costly repeat studies
Manufacturing
Adragos Pharma appoints Kostas Rengis as Chief Executive Officer
Munich, Germany – May 7th, 2026 – Adragos Pharma, a global contract development and manufacturing organisation (CDMO), today announced the appointment of Konstantinos (Kostas) Rengis as its new Chief Executive officer, succeeding Dr. Andreas Raabe, who founded the company and has led it over the past six years
Research & Development
Syngene strengthens leadership team with two key appointments to support next phase of growth
Abhijit Zutshi joins as CCO and Maninder Kapoor Puri as CHRO. India/U.S./UK, 1 May 2026: Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the Abhijit Zutshi as Chief Commercial Officer (CCO) and Maninder Kapoor Puri as Chief Human Resources Officer (CHRO), effective 1 May 2026
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology